Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Buy
52
NBIX Quote, Financials, Valuation and Earnings
Last price:
$122.87
Seasonality move
:
-5.2%
Day range:
$135.02 - $139.83
52-week range:
$84.23 - $160.18
Dividend yield:
0%
P/E ratio:
32.82x
P/S ratio:
5.24x
P/B ratio:
4.56x
Volume:
1.4M
Avg. volume:
1.1M
1-year change:
17.62%
Market cap:
$13.7B
Revenue:
$2.4B
EPS (TTM):
$4.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences, Inc.
|
$789.8M | $2.30 | 35.59% | 2401.52% | $179.59 |
|
BIO
Bio-Rad Laboratories, Inc.
|
$694.6M | $2.71 | 4.07% | -91.72% | $348.00 |
|
EW
Edwards Lifesciences Corp.
|
$1.5B | $0.62 | 12.78% | 16.3% | $96.61 |
|
MASI
Masimo Corp.
|
$408M | $1.49 | 7.08% | 565.51% | $183.75 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.19 | -69.71% | -54.94% | $7.87 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 1.25% | 39.47% | $28.63 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences, Inc.
|
$137.44 | $179.59 | $13.7B | 32.82x | $0.00 | 0% | 5.24x |
|
BIO
Bio-Rad Laboratories, Inc.
|
$293.69 | $348.00 | $7.9B | 27.23x | $0.00 | 0% | 3.16x |
|
EW
Edwards Lifesciences Corp.
|
$79.33 | $96.61 | $46B | 42.82x | $0.00 | 0% | 7.66x |
|
MASI
Masimo Corp.
|
$135.04 | $183.75 | $7.3B | 116.80x | $0.00 | 0% | 4.27x |
|
MRKR
Marker Therapeutics, Inc.
|
$1.46 | $7.87 | $24.3M | -- | $0.00 | 0% | 3.96x |
|
PFE
Pfizer Inc.
|
$27.73 | $28.63 | $157.7B | 20.46x | $0.43 | 6.2% | 2.53x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences, Inc.
|
13.77% | 1.856 | 3.43% | 2.89x |
|
BIO
Bio-Rad Laboratories, Inc.
|
17.16% | 1.271 | 18.45% | 3.62x |
|
EW
Edwards Lifesciences Corp.
|
6.42% | -0.006 | 1.21% | 2.86x |
|
MASI
Masimo Corp.
|
41.99% | 0.815 | 7.4% | 1.68x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 2.330 | -- | 5.66x |
|
PFE
Pfizer Inc.
|
39.94% | 0.402 | -- | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences, Inc.
|
$780.9M | $239.3M | 13.56% | 15.8% | 30.1% | $214.3M |
|
BIO
Bio-Rad Laboratories, Inc.
|
$342.8M | $66.4M | -8.14% | -9.77% | 10.17% | $89.2M |
|
EW
Edwards Lifesciences Corp.
|
$1.2B | $370.3M | 9.63% | 13.19% | 23.59% | $516.2M |
|
MASI
Masimo Corp.
|
$230.6M | $83.7M | -11.41% | -19.18% | 22.53% | $49.7M |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$2.1M | -103.04% | -103.04% | -173.31% | -$2.7M |
|
PFE
Pfizer Inc.
|
$12.3B | $3.7B | 5.07% | 10.84% | 21.01% | $4B |
Neurocrine Biosciences, Inc. vs. Competitors
-
Which has Higher Returns NBIX or BIO?
Bio-Rad Laboratories, Inc. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of -52.36%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Bio-Rad Laboratories, Inc.'s return on equity of -9.77%.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B BIOBio-Rad Laboratories, Inc.52.5% -$12.70 $8.1B -
What do Analysts Say About NBIX or BIO?
Neurocrine Biosciences, Inc. has a consensus price target of $179.59, signalling upside risk potential of 30.67%. On the other hand Bio-Rad Laboratories, Inc. has an analysts' consensus of $348.00 which suggests that it could grow by 18.49%. Given that Neurocrine Biosciences, Inc. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Neurocrine Biosciences, Inc. is more attractive than Bio-Rad Laboratories, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 4 0 BIOBio-Rad Laboratories, Inc.2 3 0 -
Is NBIX or BIO More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.311, which suggesting that the stock is 68.878% less volatile than S&P 500. In comparison Bio-Rad Laboratories, Inc. has a beta of 1.180, suggesting its more volatile than the S&P 500 by 18.018%.
-
Which is a Better Dividend Stock NBIX or BIO?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Rad Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Bio-Rad Laboratories, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or BIO?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are larger than Bio-Rad Laboratories, Inc. quarterly revenues of $653M. Neurocrine Biosciences, Inc.'s net income of $209.5M is higher than Bio-Rad Laboratories, Inc.'s net income of -$341.9M. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 32.82x while Bio-Rad Laboratories, Inc.'s PE ratio is 27.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.24x versus 3.16x for Bio-Rad Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.24x 32.82x $794.9M $209.5M BIOBio-Rad Laboratories, Inc.3.16x 27.23x $653M -$341.9M
-
Which has Higher Returns NBIX or EW?
Edwards Lifesciences Corp. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of 4.09%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Edwards Lifesciences Corp.'s return on equity of 13.19%.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B EWEdwards Lifesciences Corp.78.3% $0.16 $10.9B -
What do Analysts Say About NBIX or EW?
Neurocrine Biosciences, Inc. has a consensus price target of $179.59, signalling upside risk potential of 30.67%. On the other hand Edwards Lifesciences Corp. has an analysts' consensus of $96.61 which suggests that it could grow by 21.78%. Given that Neurocrine Biosciences, Inc. has higher upside potential than Edwards Lifesciences Corp., analysts believe Neurocrine Biosciences, Inc. is more attractive than Edwards Lifesciences Corp..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 4 0 EWEdwards Lifesciences Corp.16 12 0 -
Is NBIX or EW More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.311, which suggesting that the stock is 68.878% less volatile than S&P 500. In comparison Edwards Lifesciences Corp. has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.133%.
-
Which is a Better Dividend Stock NBIX or EW?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edwards Lifesciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Edwards Lifesciences Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or EW?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are smaller than Edwards Lifesciences Corp. quarterly revenues of $1.6B. Neurocrine Biosciences, Inc.'s net income of $209.5M is higher than Edwards Lifesciences Corp.'s net income of $64.2M. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 32.82x while Edwards Lifesciences Corp.'s PE ratio is 42.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.24x versus 7.66x for Edwards Lifesciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.24x 32.82x $794.9M $209.5M EWEdwards Lifesciences Corp.7.66x 42.82x $1.6B $64.2M
-
Which has Higher Returns NBIX or MASI?
Masimo Corp. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of 14.46%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Masimo Corp.'s return on equity of -19.18%.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B MASIMasimo Corp.62.07% -$1.86 $1.4B -
What do Analysts Say About NBIX or MASI?
Neurocrine Biosciences, Inc. has a consensus price target of $179.59, signalling upside risk potential of 30.67%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 36.07%. Given that Masimo Corp. has higher upside potential than Neurocrine Biosciences, Inc., analysts believe Masimo Corp. is more attractive than Neurocrine Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 4 0 MASIMasimo Corp.4 3 0 -
Is NBIX or MASI More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.311, which suggesting that the stock is 68.878% less volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.165%.
-
Which is a Better Dividend Stock NBIX or MASI?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or MASI?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are larger than Masimo Corp. quarterly revenues of $371.5M. Neurocrine Biosciences, Inc.'s net income of $209.5M is higher than Masimo Corp.'s net income of $53.7M. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 32.82x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.24x versus 4.27x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.24x 32.82x $794.9M $209.5M MASIMasimo Corp.4.27x 116.80x $371.5M $53.7M
-
Which has Higher Returns NBIX or MRKR?
Marker Therapeutics, Inc. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of -162.11%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M -
What do Analysts Say About NBIX or MRKR?
Neurocrine Biosciences, Inc. has a consensus price target of $179.59, signalling upside risk potential of 30.67%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 438.81%. Given that Marker Therapeutics, Inc. has higher upside potential than Neurocrine Biosciences, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Neurocrine Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 4 0 MRKRMarker Therapeutics, Inc.3 0 0 -
Is NBIX or MRKR More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.311, which suggesting that the stock is 68.878% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.442, suggesting its more volatile than the S&P 500 by 44.218%.
-
Which is a Better Dividend Stock NBIX or MRKR?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or MRKR?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Neurocrine Biosciences, Inc.'s net income of $209.5M is higher than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 32.82x while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.24x versus 3.96x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.24x 32.82x $794.9M $209.5M MRKRMarker Therapeutics, Inc.3.96x -- $1.2M -$2M
-
Which has Higher Returns NBIX or PFE?
Pfizer Inc. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of -9.34%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B PFEPfizer Inc.69.97% -$0.29 $154.8B -
What do Analysts Say About NBIX or PFE?
Neurocrine Biosciences, Inc. has a consensus price target of $179.59, signalling upside risk potential of 30.67%. On the other hand Pfizer Inc. has an analysts' consensus of $28.63 which suggests that it could grow by 3.24%. Given that Neurocrine Biosciences, Inc. has higher upside potential than Pfizer Inc., analysts believe Neurocrine Biosciences, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 4 0 PFEPfizer Inc.7 15 1 -
Is NBIX or PFE More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.311, which suggesting that the stock is 68.878% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.
-
Which is a Better Dividend Stock NBIX or PFE?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.2% to investors and pays a quarterly dividend of $0.43 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or PFE?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Neurocrine Biosciences, Inc.'s net income of $209.5M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 32.82x while Pfizer Inc.'s PE ratio is 20.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.24x versus 2.53x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.24x 32.82x $794.9M $209.5M PFEPfizer Inc.2.53x 20.46x $17.6B -$1.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
